Continuity Biosciences
Bradenton, US · Founded 2023 · Delaware LLC · 1 known investors
Continuity Biosciences develops adaptive precision drug-delivery platforms that combine engineering and biology to help therapies reach their intended targets more effectively. The company works across multiple therapeutic applications rather than a single drug or disease, bridging medtech and biotech.
Founders & leadership
Continuity Biosciences was founded in 2023 by Ramakrishna Venugopalan.
RV
Ramakrishna VenugopalanCo-Founder & Chief Executive Officer
RW
Robert WhiteheadCo-Founder & Executive Chair
Board
AG
Alessandro GrattoniChief Scientific Advisor
Investors · 1
Reported raises · per SEC filings
Form D private placements$11.9M disclosed across 3 rounds · 2024–2025
▶$8.4MraisedAug 2025 · 13 investors · BiotechnologyRule 506(b)
▶$8.4MraisedAug 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael L. FowlerDirector
- Allen R. WeissDirector
- Monica P. ReedDirector
- Joseph DeSimoneDirector
- Ramakrishna VenugopalanExecutive Officer, Director
- Robert WhiteheadDirector
- Josephine TorrenteDirector
- Offering amount
- $12M
- Amount sold
- $8.4M
- First sale
- Aug 2025
- Incorporated
- Limited Liability Company, Delaware, 2023
- Federal exemptions
- 06b
▶$1MraisedJun 2025 · 13 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ramakrishna VenugopalanExecutive Officer, Director
- Robert WhiteheadDirector
- Allen R. WeissDirector
- Michael L. FowlerDirector
- Monica P. ReedDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- May 2025
- Incorporated
- Limited Liability Company, Delaware, 2023
- Federal exemptions
- 06b
▶$2.5MraisedJul 2024 · 10 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJul 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WhiteheadExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.5M
- First sale
- Jun 2024
- Incorporated
- Limited Liability Company, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapPrecision BioSciences13 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Life Biosciences8 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
IQVIA8 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Intuitive Biosciences8 shared keywordsIntuitive Bio develops immunoassays and diagnostic products and services, including non-human primate viral and TB tests and test processing, for research laboratories. The company offers assay development from proof of concept to fully-validated assays in a multiplex format supporting 1–100 markers per well.
Solid Biosciences6 shared keywordsSolid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
Companies competing with Continuity Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Continuity Biosciences do?
- Continuity Biosciences develops adaptive precision drug-delivery platforms that combine engineering and biology to help therapies reach their intended targets more effectively. The company works across multiple therapeutic applications rather than a single drug or disease, bridging medtech and biotech.
- Who founded Continuity Biosciences?
- Continuity Biosciences was founded by Ramakrishna Venugopalan in 2023.
- Who are Continuity Biosciences's investors?
- Continuity Biosciences's investors include MERGING TRAFFIC.
- How much funding has Continuity Biosciences raised?
- Continuity Biosciences has disclosed $11.9M raised across 3 rounds.
- Where is Continuity Biosciences headquartered?
- Continuity Biosciences is headquartered in Bradenton, US.